Printer Friendly

SRI International Announces New Vaccine Development Director, Rae Lyn Burke.

Business Editors & Health/Medical Writers

MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 3, 2002

SRI International, a leading independent research institute based in Silicon Valley, announced today that Rae Lyn Burke, Ph.D., has joined SRI as senior director of vaccine and biotherapeutics development for its Biopharmaceutical Division. The division provides a full range of services to pharmaceutical companies and government agencies such as the National Institutes of Health (NIH).

For the past four years, Dr. Burke was founder and principal of Biotechnology Solutions, a consulting group specializing in the research and development of biological therapeutics, from initial discovery through clinical evaluation. For 16 years prior, Dr. Burke was senior director of virology and vaccine research for Chiron. At Chiron, she participated in the development of the hepatitis B vaccine and in the cloning and production of key proteins involved in blood clotting. Dr. Burke oversaw the development of vaccines and diagnostics for herpes viruses. This work pioneered the concept of using vaccines in novel ways, as immunotherapeutics, not merely to prevent but also to treat chronic diseases.

While at Biotechnology Solutions, Dr. Burke worked with SRI on the development of promising HIV vaccine candidates. One of these projects is in connection with researchers at a major U.S. university who, with funding from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the NIH, have developed an HIV-1 vaccine that in animal models does not prevent HIV infection but seems to help the body control the AIDS virus. SRI scientists recently completed preclinical safety testing on the vaccine, completing all the steps required to move it into Phase I clinical trials in humans. SRI prepared the Investigational New Drug (IND) application for submission to the Food and Drug Administration (FDA) by NIAID, sponsor of the IND. The FDA has recently given approval to start the Phase I human clinical trial.

SRI also recently performed the preclinical safety work for an emerging biopharmaceutical company's HIV vaccine, another vaccine product supported by NIAID funding. The biopharmaceutical company has received clearance from FDA to start a Phase I/II clinical trial of the vaccine.

Dr. Burke has participated in the design and implementation of more than 30 clinical trials, is an author of 80 publications, holds 28 patents, and has been an invited speaker for more than 50 presentations. She received a Ph.D. in Microbiology from the State University of New York, Stony Brook and did postdoctoral studies at the University of California, San Francisco in the laboratory of Dr. Bruce Alberts.

About SRI's Biopharmaceutical Division

SRI International's Biopharmaceutical Division ( offers government and commercial clients a broad range of preclinical discovery and development services, including efficacy and safety evaluations, pharmacokinetics and metabolism studies, analytical chemistry and formulation design and production in a GLP and cGMP environment. SRI, one of the most productive sources of new drug entities outside the established pharmaceutical industry, also works with clients to pursue lead compounds and advance research of therapeutics and vaccines in cancer, neuroscience, and infectious diseases.

About SRI International

Silicon Valley-based SRI International ( is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 55 years. The nonprofit research institute performs contract research and development for government agencies, commercial businesses and nonprofit foundations. SRI is well known for its innovations in information technology, telecommunications, engineering, pharmaceuticals, chemistry, physics, and the public policy areas of education, health, and economic development. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:SRI International Announces New Vaccine Development Director, Rae Lyn Burke.
Publication:Business Wire
Geographic Code:1USA
Date:Sep 3, 2002
Previous Article:SchlumbergerSema Cyberflex JavaCard Obtains Common Criteria EAL4+ Security Certification.
Next Article:ProCyte Corporation To Present At Redchip Partners Investor Conference in New York- SEPT. 19, 2002 Steve Forbes, Editor-in-Chief of Forbes Magazine,...

Related Articles
Protecting our children. (Advice and dissent: letters from our readers).
Port takes title pursuit to next level.
National Cancer Institute Selects SRI International Breast Cancer Therapeutic for Further Development.
SRI International, Memorial Sloan-Kettering and Southern Research Institute License Phase II Oncology Drug to Allos Therapeutics.
Lawyers, Lawsuits, and Legal Rights.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters